IntegraGen SA (BST:7N8)

Germany · Delayed Price · Currency is EUR

0.0634

-0.0104 (-14.09%)

At close: Oct 29, 2026

Market Cap	428.65K -58.2%
Revenue (ttm)	5.02M -42.3%
Net Income	-2.66M
EPS	-0.40
Shares Out	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Open	0.0620
Previous Close	0.0738
Day's Range	0.0620 - 0.0750
52-Week Range	0.0130 - 0.3320
Beta	n/a
Analysts	n/a
Price Target	n/a
Est. Earnings	Apr 26, 2027

About IntegraGen

IntegraGen SA provides researchers with sequencing solutions, data management tools, and biostatistical, and bioinformatics support services in France. The company’s genomic pharma services DNA sequencing for oncology and rare disease research; and NGS testing for cancer research. It also provides MERCURY, an online biological interpretation tool for oncology intended to assist pathologists and oncologists in transforming raw data obtained through high-throughput sequencing into a molecular report for translational and clinical research use; Ga... [Read more]

Industry Biotechnology

Sector Healthcare

Founded 2000

Employees 37

Stock Exchange Stuttgart Stock Exchange

Ticker Symbol 7N8

Financial Performance

In 2025, IntegraGen's revenue was 5.02 million, a decrease of -42.27% compared to the previous year's 8.70 million. Losses were -2.66 million, 940.6% more than in 2024.

Financial Statements